Skip to Main Content

Paper Details

Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.
J Mol Diagn
2
2023
AKT, ALK, BRAF, BRAF-Negative Melanoma, Bcl2, Circulating Tumor DNA, Circulating tumor DNA, MET, Patients, cancers, ctDNA, ctDNA variants, cyclin-dependent kinase 4/6, epidermal growth factor receptor, late-stage melanoma, mTOR, mammalian target, melanoma, pan-cancer gene panel, patient, patients, phosphatidylinositol, phosphatidylinositol 3-kinase, plasma, rapamycin, stage IV melanoma, vascular endothelial growth factor receptor
Author NameAffiliation
Nicola WaddellQIMR Berghofer Medical Research Institute
Nicola WaddellQIMR Berghofer Medical Research Institute
  • 1 - 2

Datasets

Release 1.2